|
Note: mc10 maintains press releases and news on this site for archival purposes. Press releases are believed accurate as of the date they are issued; however, they may become outdated over time, and should not be relied on as correct after their issue date. mc10 is not responsible for the quality of third party content.
|
MC10 Accepts $2M Follow On Investment From Aberdare Ventures, the Leading Investment Firm Focused on the Convergence of Healthcare and TechnologyAberdare’s Unique Expertise in Wearable and Wireless Health Supports the Advancement of MC10’s innovative “Seamless Sensing” Devices in Healthcare Cambridge, Mass. – January 26, 2012 – MC10 Inc. today announced it has closed on a $2 million investment from Aberdare Ventures and added managing partner, Paul Klingenstein, to its board of directors. Based in San Francisco, Aberdare Ventures invests in companies that are transforming healthcare, and its investment in MC10 underscores the company’s unique opportunity to reshape electronics in the healthcare industry. MC10 takes high-performance electronics ‘out-of-the-box’ and into new products that blur the lines between user and device. The company is developing a variety of products including interventional circuits that can diagnose and influence tissue function and ‘seamless sensing’ devices that can monitor key aspects of performance such as the heart (ECG), the brain (EEG), muscles (EMG), body temperature, and hydration. “After meeting the Aberdare team it became extremely clear that the firm is immersed in the markets MC10 is pursuing and that their input will add significant value to our efforts,” said David Icke, CEO of MC10 Inc. “Paul and the team at Aberdare share our belief that the convergence of technology and healthcare holds tremendous value and MC10’s approach in this space is a game changer.” Aberdare Ventures invests in visionary entrepreneurs and technologies that are transforming healthcare around the world. Representative past Aberdare investments include Pharmion, Ironwood Pharmaceuticals, and Ablation Frontiers. Aberdare’s current portfolio includes leading companies at the convergence of efficient healthcare and next generation technologies such as Clovis Pharmaceuticals, Aviir, Sonitus Medical, Jiff, goBalto, and Rock Health. “We love this team and their technology,” said Paul Klingenstein, managing partner at Aberdare Ventures. “Stretchable and conformable integrated circuits have the potential to transform healthcare, and likely other fields as well. This investment is perfectly consistent with the Aberdare strategy: to support leading technologies that can make healthcare more efficient and less costly.”
About Aberdare Ventures
About MC10 |